Clinicopathological Impact of ABCC1/MRP1 and ABCC4/MRP4 in Epithelial Ovarian Carcinoma
Open Access
- 1 January 2013
- journal article
- research article
- Published by Hindawi Limited in BioMed Research International
- Vol. 2013, 1-7
- https://doi.org/10.1155/2013/143202
Abstract
Ovarian cancer is the main cause of death from gynaecological malignancies. In spite of the efficacy of platinum-paclitaxel treatment in patients with primary epithelial ovarian carcinoma, platinum-based chemotherapy is not curative and resistance remains one of the most important causes of treatment failure. Although ABC transporters have been implicated in cellular resistance to multiple drugs, the clinical relevance of these efflux pumps is still poorly understood. Thus, we examined the prognostic role of transporters of the MRP family (i.e., ABCC1/MRP1, ABCC4/MRP4) to gain insights into their clinical impacts. A case material of 127 patients with ovarian carcinoma at different stages and histotypes was used. The expression of MRP1 and MRP4 was examined by immunohistochemistry using tissue microarrays in tumor specimens collected at the time of initial surgery expression. We found an association between MRP1 expression and grading, and we observed that MRP4 displayed an unfavourable impact on disease relapse in multivariate analysis (HR = 2.05, 95% CI: 1.01–4.11;). These results suggest that in epithelial ovarian cancer, MRP1 may be a marker for aggressiveness because its expression was associated with tumor grade and support that MRP4 may play an unfavourable role in disease outcome.
Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro, Italy
This publication has 23 references indexed in Scilit:
- Rethinking ovarian cancer: recommendations for improving outcomesNature Reviews Cancer, 2011
- Achievements and unmet needs in the management of advanced ovarian cancerGynecologic Oncology, 2010
- Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatmentProceedings of the National Academy of Sciences, 2009
- The biology of ovarian cancer: new opportunities for translationNature Reviews Cancer, 2009
- Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancerGynecologic Oncology, 2009
- Expression of multidrug resistance‐associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell originLiver International, 2008
- Chemotherapy-induced resistance by ATP-binding cassette transporter genesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2007
- Microarrays as Validation Strategies in Clinical Samples: Tissue and Protein MicroarraysOMICS: A Journal of Integrative Biology, 2006
- M‐CAM expression as marker of poor prognosis in epithelial ovarian cancerInternational Journal of Cancer, 2006
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002